Abstract
Esophageal squamous cell carcinomas (ESCC) are usually asymptomatic and go undetected until they are incurable. Cytological screening is one strategy to detect ESCC at an early stage and has shown promise in previous studies, although improvement in sensitivity and specificity are needed. Proteases modulate cancer progression by facilitating tumor invasion and metastasis. In the current study, matrix metalloproteinases (MMPs) were studied in a search for new early detection markers for ESCC. Protein expression levels of MMPs were measured using zymography in 24 cases of paired normal esophagus and ESCC, and in the tumor-associated stroma and tumor epithelium in one sample after laser capture microdissection (LCM). MMP-3 and MMP-10 transcripts in both the epithelium and stroma in five cases were further analyzed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Gelatin zymography showed bands corresponding in size to MMP-2, MMP-3, MMP-9, and MMP-10 enzymes in each of the 24 cancer cases. MMP levels tended to be higher in tumors than paired normal tissue; however, only the 45 kDa band that corresponds to the activated form of MMP-3 and MMP-10 was strongly expressed in all 24 tumors with little or no expression in the paired normal foci. LCM-based analysis showed the 45 kDA band to be present in both the stromal and epithelial components of the tumor microenvironment, and that MMP-3 and MMP-10 mRNA levels were higher in tumors than paired normal tissues for each compartment. Increased levels of MMPs occur in ESCC suggesting their up-regulation is important in esophageal tumorigenesis. The up-regulated gene products have the potential to serve as early detection markers in the clinic.
MeSH Terms
Adult
Aged
Carcinoma, Squamous Cell/enzymology,pathology
Enzyme Activation
Esophageal Neoplasms/enzymology,pathology
Female
Humans
Male
Matrix Metalloproteinases/metabolism
Middle Aged
Polymerase Chain Reaction
Chemicals
Matrix Metalloproteinases
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Mukherjee Sumana
Pathogenetics Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Roth Mark J
Dawsey Sanford M
Yan Wusheng
Rodriguez-Canales Jaime
Erickson Heidi S
Hu Nan
Goldstein Alisa M
Taylor Philip R
Richardson Annely M
Tangrea Michael A
Chuaqui Rodrigo F
Emmert-Buck Michael R
References (21)
21 references, click to expand
-
How matrix metalloproteinases regulate cell behavior.
Annu Rev Cell Dev Biol. 2001;17:463-516
PMID: 11687497
-
Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications.
Cancer Detect Prev. 2002;26(3):222-8
PMID: 12269770
-
[Liquid-based cytology for esophageal carcinoma screening].
Ai Zheng. 2009 Dec;28(12):1243-7
PMID: 19958616
-
Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
Gerontology. 2011;57(1):44-52
PMID: 20215736
-
Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.
J Cancer Res Clin Oncol. 2004 Jan;130(1):37-44
PMID: 14569466
-
Matrix metalloproteinases as modulators of inflammation and innate immunity.
Nat Rev Immunol. 2004 Aug;4(8):617-29
PMID: 15286728
-
Assessment of normalization strategies for quantitative RT-PCR using microdissected tissue samples.
Lab Invest. 2007 Sep;87(9):951-62
PMID: 17643124
-
New functions for the matrix metalloproteinases in cancer progression.
Nat Rev Cancer. 2002 Mar;2(3):161-74
PMID: 11990853
-
Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Llinxian, China.
Acta Cytol. 2008 Jan-Feb;52(1):14-23
PMID: 18323271
-
Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
Clin Cancer Res. 2003 Feb;9(2):551-4
PMID: 12576417
-
Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Hepatogastroenterology. 2007 Jul-Aug;54(77):1591-5
PMID: 17708308
-
Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.
Dis Esophagus. 2009;22(8):664-7
PMID: 19191857
-
Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90.
Int J Cancer. 2002 Nov 20;102(3):271-4
PMID: 12397650
-
CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma.
Cancer. 2004 Nov 1;101(9):1994-2000
PMID: 15372476
-
Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study.
Cancer. 1992 Dec 15;70(12):2747-53
PMID: 1451050
-
Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma.
Am J Gastroenterol. 2005 Aug;100(8):1835-43
PMID: 16086722
-
Value of endoscopic methylene blue and Lugol's iodine double staining and detection of GST-Pi and telomerase in the early diagnosis of esophageal carcinoma.
World J Gastroenterol. 2005 Oct 21;11(39):6090-5
PMID: 16273632
-
Global cancer statistics, 2002.
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
PMID: 15761078
-
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.
Circ Res. 2003 May 2;92(8):827-39
PMID: 12730128
-
Expression of activated gelatinase in human invasive breast carcinoma.
Clin Exp Metastasis. 1993 Mar;11(2):183-9
PMID: 8444010
-
Regulation of matrix metalloproteinase expression in tumor invasion.
FASEB J. 1999 May;13(8):781-92
PMID: 10224222